. ORs and 95% CIs of individual studies and pooled data; comparison of endovascular intervention and surgical revascularization for restenosis.
Background: A better understanding of the patients' perspectives is pivotal in the development of patient-reported outcomes (PROs) in vasculitis. Objectives: To assessed patients' perspective of disease amongst cases with Giant Cell Arteritis (GCA) compared to comparator illnesses mimicking large vessel vasculitis (LVV) included in the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS) database. Methods: Patient Description of Illness (PDI) forms were circulated amongst Centres participating in the DCVAS study. The PDI form records up to 10 free-text severity ranked symptoms in descending order of severity, a body-map to localise the sites of pain and a free-text short summary of illness description. Free text was reorganized through content and thematic analysis. Results: PDI forms from 89 patients with GCA and 28 comparators (COM) were analysed. There was no difference in age and sex distribution between groups (mean age 70±8 for GCA and 69±12 for COM). The symptoms description and frequency of the first most severe aspect of disease, including the patient's own words, is presented in Of them, 9 patients with PMR agreed to the proposal of TCZ addition, and their therapeutic responses to TCZ and its safety were determined. They were at the age of 68.2±10.6, including three males and six females. Before TCZ addition, the patients were treated with prednisolone (PSL) at 7.6±3.0 mg/day plus MTX at 7.1±5.1 mg/week, and serum CRP were at 1.0±1.0 mg/dL. After 8.4±5.7 months of TCZ treatment, PSL and MTX had been reduced to 1.1±1.3 mg/day and 3.3±4.5 mg/week, respectively, with CRP at 0.02±0 mg/dL. GC were able to be withdrawn in 5 patients, and MTX were further withdrawn in 4 patients. Two patients reached drug-free remission (PMR-AS=0.02). During TCZ therapy, each one patient showed the worsening of depression and occlusion of the central retinal vein.
Conclusions:
These results indicate that TCZ may provide a therapeutic option for patients with severe PMR who were resistant or intolerant to GC and additional MTX. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5945
